累及口腔的IgG4相关疾病研究进展

doi:10.13591/j.cnki.kqyx.2023.12.010

摘要/Abstract

摘要：

IgG4相关疾病(immunoglobulin G4-related disease,IgG4-RD)是一种病因不明的全身性多器官纤维炎性疾病,研究认为B细胞和T细胞的增殖活化及其相互作用在该病的免疫反应及纤维化过程中可能发挥重要作用。IgG4-RD可累及包括口腔在内的多个器官和系统。唾液腺是口腔内最常受累的器官,此外,口腔的其他组织也可被IgG4-RD累及,且临床表现异质,临床准确诊断存在困难。为此,该文检索近年来IgG4-RD累及口腔组织的文献报道,结合最新诊断标准,从流行病学、发病机制、临床表现、诊断与治疗出发作一综述。

关键词: IgG4相关疾病, 口腔, 发病机制, 诊断, 治疗

Abstract:

IgG4-related disease (IgG4-RD) is a systemic multi-organ fibroinflammatory disease of unknown etiology. Studies suggest that the proliferation and activation of B cells, T cells and their crosstalk may play important roles in the immune response and fibrosis process of the disease. IgG4-RD can involve multiple organs and systems including the maxillofacial region. Salivary glands are the most frequently involved organs in the oral cavity. In addition, other tissues in the oral cavity can also be affected, and the clinical manifestations are heterogeneous. It is difficult to make accurate clinical diagnosis. To this end, this article searches literature reports of IgG4-RD involving oral tissue in recent years, and reviews the IgG4-RD involving oral cavity from the perspective of epidemiology, pathogenesis, clinical manifestation, diagnosis and treatment, combined with the latest diagnostic criteria.

Key words: IgG4-related disease, oral cavity, pathogenesis, diagnosis, treatment

中图分类号:

R781.9

张天玉,江潞. 累及口腔的IgG4相关疾病研究进展[J]. 口腔医学, 2023, 43(12): 1106-1111.

ZHANG Tianyu,JIANG Lu. Research progress of IgG4-related disease in oral cavity[J]. Stomatology, 2023, 43(12): 1106-1111.

图/表 2

参考文献 50

[1]	Kamisawa T, Zen Y, Pillai S, et al. IgG4-related disease[J]. Lancet, 2015, 385(9976):1460-1471. doi: 10.1016/S0140-6736(14)60720-0 pmid: 25481618
[2]	Brito-Zerón P, Ramos-Casals M, Bosch X, et al. The clinical spectrum of IgG4-related disease[J]. Autoimmun Rev, 2014, 13(12):1203-1210. doi: 10.1016/j.autrev.2014.08.013 pmid: 25151972
[3]	Uchida K, Masamune A, Shimosegawa T, et al. Prevalence of IgG4-related disease in Japan based on nationwide survey in 2009[J]. Int J Rheumatol, 2012, 2012:358371.
[4]	Lanzillotta M, Fernàndez-Codina A, Culver E, et al. Emerging therapy options for IgG4-related disease[J]. Expert Rev Clin Immunol, 2021, 17(5):471-483. doi: 10.1080/1744666X.2021.1902310
[5]	Kawa S, Ota M, Yoshizawa K, et al. HLA DRB10405-DQB10401 haplotype is associated with autoimmune pancreatitis in the Japanese population[J]. Gastroenterology, 2002, 122(5):1264-1269. doi: 10.1053/gast.2002.33022
[6]	Perugino CA, AlSalem SB, Mattoo H, et al. Identification of galectin-3 as an autoantigen in patients with IgG₄-related disease[J]. J Allergy Clin Immunol, 2019, 143(2):736-745.e6. doi: S0091-6749(18)30768-1 pmid: 29852256
[7]	Shiokawa M, Kodama Y, Sekiguchi K, et al. Laminin 511 is a target antigen in autoimmune pancreatitis[J]. Sci Transl Med, 2018, 10(453):eaaq0997.
[8]	Hubers LM, Vos H, Schuurman AR, et al. Annexin A11 is targeted by IgG4 and IgG1 autoantibodies in IgG4-related disease[J]. Gut, 2018, 67(4):728-735. doi: 10.1136/gutjnl-2017-314548 pmid: 28765476
[9]	Sasaki T, Akiyama M, Kaneko Y, et al. Risk factors of relapse following glucocorticoid tapering in IgG4-related disease[J]. Clin Exp Rheumatol, 2018, 36 Suppl 112(3):186-189. pmid: 29846165
[10]	Tang JG, Cai SZ, Ye C, et al. Biomarkers in IgG4-related disease:A systematic review[J]. Semin Arthritis Rheum, 2020, 50(2):354-359. doi: 10.1016/j.semarthrit.2019.06.018
[11]	Della-Torre E, Rigamonti E, Perugino C, et al. B lymphocytes directly contribute to tissue fibrosis in patients with IgG₄-related disease[J]. J Allergy Clin Immunol, 2020, 145(3):968-981.e14. doi: S0091-6749(19)30936-4 pmid: 31319101
[12]	Kubo S, Nakayamada S, Zhao JD, et al. Correlation of T follicular helper cells and plasmablasts with the development of organ involvement in patients with IgG4-related disease[J]. Rheumatology (Oxford), 2018, 57(3):514-524. doi: 10.1093/rheumatology/kex455 pmid: 29253269
[13]	Tsuboi H, Matsuo N, Iizuka M, et al. Analysis of IgG4 class switch-related molecules in IgG4-related disease[J]. Arthritis Res Ther, 2012, 14(4):R171. doi: 10.1186/ar3924
[14]	Kusuda T, Uchida K, Miyoshi H, et al. Involvement of inducible costimulator- and interleukin 10-positive regulatory T cells in the development of IgG4-related autoimmune pancreatitis[J]. Pancreas, 2011, 40(7):1120-1130. doi: 10.1097/MPA.0b013e31821fc796
[15]	Perugino CA, Kaneko N, Maehara T, et al. CD4⁺ and CD8⁺ cytotoxic T lymphocytes may induce mesenchymal cell apoptosis in IgG₄-related disease[J]. J Allergy Clin Immunol, 2021, 147(1):368-382. doi: 10.1016/j.jaci.2020.05.022 pmid: 32485263
[16]	Perugino CA, Stone JH. IgG4-related disease:An update on pathophysiology and implications for clinical care[J]. Nat Rev Rheumatol, 2020, 16(12):702-714. doi: 10.1038/s41584-020-0500-7
[17]	Ji ZF, Chen RY, Cui XM, et al. In vitro IL-6/IL-6R trans-signaling in fibroblasts releases cytokines that may be linked to the pathogenesis of IgG4-related disease[J]. Front Immunol, 2020, 11:1272. doi: 10.3389/fimmu.2020.01272 pmid: 32733444
[18]	Yamada K, Yamamoto M, Saeki T, et al. New clues to the nature of immunoglobulin G4-related disease:A retrospective Japanese multicenter study of baseline clinical features of 334 cases[J]. Arthritis Res Ther, 2017, 19(1):262. doi: 10.1186/s13075-017-1467-x
[19]	Inoue D, Yoshida K, Yoneda N, et al. IgG4-related disease:Dataset of 235 consecutive patients[J]. Medicine, 2015, 94(15):e680. doi: 10.1097/MD.0000000000000680
[20]	Li W, Chen Y, Sun ZP, et al. Clinicopathological characteristics of immunoglobulin G4-related sialadenitis[J]. Arthritis Res Ther, 2015, 17(1):186. doi: 10.1186/s13075-015-0698-y
[21]	朱轩智, 张尽美, 吴亚菲, 等. 以牙龈增生为特征的IgG4相关性疾病1例[J]. 中华口腔医学杂志, 2022, 57(8):867-870.
[22]	Gontarz M, Wyszyńska-Pawelec G, Zapała J, et al. IgG4-related disease in the head and neck region:Report of two cases and review of the literature[J]. Pol J Pathol, 2016, 67(4):370-375. doi: 29480 pmid: 28547965
[23]	Zhang JM, Zhao L, Zhou JY, et al. Immunoglobulin G4-related periodontitis:Case report and review of the literature[J]. BMC Oral Health, 2021, 21(1):279. doi: 10.1186/s12903-021-01592-2
[24]	Cottom H, Mighell AJ, High A, et al. Are plasma cell-rich inflammatory conditions of the oral mucosa manifestations of IgG4-related disease?[J]. J Clin Pathol, 2015, 68(10):802-807. doi: 10.1136/jclinpath-2014-202814 pmid: 26056156
[25]	Bukhari AF, Magnuson BE, Desai B, et al. Diffuse palatal swelling[J]. Oral Surg Oral Med Oral Pathol Oral Radiol, 2021, 131(3):269-275. doi: 10.1016/j.oooo.2019.12.003
[26]	Laco J, Kamarádová K, Mottl R, et al. Plasma cell granuloma of the oral cavity—a mucosal manifestation of immunoglobulin G4-related disease or a mimic?[J]. Virchows Arch, 2015, 466(3):255-263. doi: 10.1007/s00428-014-1711-6
[27]	Hashemi H, Thor A, Hellbacher E, et al. Localized IgG4-related disease manifested on the tongue:A case report[J]. Ups J Med Sci, 2021:126.
[28]	Ali Khurram S, Fernando M, Smith AT, et al. IgG4-related sclerosing disease clinically mimicking oral squamous cell carcinoma[J]. Oral Surg Oral Med Oral Pathol Oral Radiol, 2013, 115(2):e48-e51.
[29]	Andrew N, Kearney D, Sladden N, et al. Immunoglobulin G4-related disease of the hard palate[J]. J Oral Maxillofac Surg, 2014, 72(4):717-723. doi: 10.1016/j.joms.2013.08.033
[30]	张文, 董凌莉, 朱剑, 等. IgG 4相关性疾病诊治中国专家共识[J]. 中华内科杂志, 2021, 60(3):192-206.
[31]	Stone JH, Zen Y, Deshpande V. IgG4-related disease[J]. N Engl J Med, 2012, 366(6):539-551. doi: 10.1056/NEJMra1104650
[32]	Carruthers MN, Khosroshahi A, Augustin T, et al. The diagnostic utility of serum IgG4 concentrations in IgG4-related disease[J]. Ann Rheum Dis, 2015, 74(1):14-18. doi: 10.1136/annrheumdis-2013-204907 pmid: 24651618
[33]	Ebbo M, Grados A, Bernit E, et al. Pathologies associated with serum IgG4 elevation[J]. Int J Rheumatol, 2012, 2012:602809.
[34]	Sah RP, Chari ST. Serologic issues in IgG4-related systemic disease and autoimmune pancreatitis[J]. Curr Opin Rheumatol, 2011, 23(1):108-113. doi: 10.1097/BOR.0b013e3283413469 pmid: 21124093
[35]	Umehara H, Okazaki K, Masaki Y, et al. Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011[J]. Mod Rheumatol, 2012, 22(1):21-30. doi: 10.1007/s10165-011-0571-z pmid: 22218969
[36]	Umehara H, Okazaki K, Kawa S, et al. The 2020 revised comprehensive diagnostic (RCD) criteria for IgG4-RD[J]. Mod Rheumatol, 2021, 31(3):529-533. doi: 10.1080/14397595.2020.1859710
[37]	Deshpande V, Zen Y, Chan JK, et al. Consensus statement on the pathology of IgG4-related disease[J]. Mod Pathol, 2012, 25(9):1181-1192. doi: 10.1038/modpathol.2012.72
[38]	Khosroshahi A, Wallace ZS, Crowe JL, et al. International consensus guidance statement on the management and treatment of IgG4-related disease[J]. Arthritis Rheumatol, 2015, 67(7):1688-1699. doi: 10.1002/art.v67.7
[39]	Okazaki K, Chari ST, Frulloni L, et al. International consensus for the treatment of autoimmune pancreatitis[J]. Pancreatology, 2017, 17(1):1-6. doi: S1424-3903(16)31250-9 pmid: 28027896
[40]	Kawa S, Okazaki K, Kamisawa T, et al. Amendment of the Japanese Consensus Guidelines for Autoimmune Pancreatitis, 2013 II. Extrapancreatic lesions, differential diagnosis[J]. J Gastroenterol, 2014, 49(5):765-784. doi: 10.1007/s00535-014-0944-0 pmid: 24664402
[41]	Sugimoto M, Takagi T, Suzuki R, et al. Efficacy of steroid pulse therapy for autoimmune pancreatitis type 1:A retrospective study[J]. PLoS One, 2015, 10(9):e0138604.
[42]	Wu QJ, Chang J, Chen H, et al. Efficacy between high and medium doses of glucocorticoid therapy in remission induction of IgG4-related diseases:A preliminary randomized controlled trial[J]. Int J Rheum Dis, 2017, 20(5):639-646. doi: 10.1111/apl.2017.20.issue-5
[43]	Moriyama M, Tanaka A, Maehara T, et al. Clinical characteristics of Mikulicz’s disease as an IgG4-related disease[J]. Clin Oral Invest, 2013, 17(9):1995-2002. doi: 10.1007/s00784-012-0905-z
[44]	Fei YY, Chen Y, Zhang PP, et al. Efficacy of Cyclophosphamide treatment for immunoglobulin G4-related disease with addition of glucocorticoids[J]. Sci Rep, 2017, 7(1):6195. doi: 10.1038/s41598-017-06520-5 pmid: 28733656
[45]	Mattoo H, Mahajan VS, Maehara T, et al. Clonal expansion of CD4⁺ cytotoxic T lymphocytes in patients with IgG₄-related disease[J]. J Allergy Clin Immunol, 2016, 138(3):825-838. doi: S0091-6749(16)00198-6 pmid: 26971690
[46]	Carruthers MN, Topazian MD, Khosroshahi A, et al. Rituximab for IgG4-related disease:A prospective, open-label trial[J]. Ann Rheum Dis, 2015, 74(6):1171-1177. doi: 10.1136/annrheumdis-2014-206605 pmid: 25667206
[47]	Ebbo M, Grados A, Samson M, et al. Long-term efficacy and safety of rituximab in IgG4-related disease:Data from a French nationwide study of thirty-three patients[J]. PLoS One, 2017, 12(9):e0183844.
[48]	Campochiaro C, Della-Torre E, Lanzillotta M, et al. Long-term efficacy of maintenance therapy with Rituximab for IgG4-related disease[J]. Eur J Intern Med, 2020, 74:92-98. doi: S0953-6205(19)30467-4 pmid: 31901297
[49]	Della-Torre E, Feeney E, Deshpande V, et al. B-cell depletion attenuates serological biomarkers of fibrosis and myofibroblast activation in IgG4-related disease[J]. Ann Rheum Dis, 2015, 74(12):2236-2243. doi: 10.1136/annrheumdis-2014-205799 pmid: 25143523
[50]	Shimizu Y, Yamamoto M, Naishiro Y, et al. Necessity of early intervention for IgG4-related disease:Delayed treatment induces fibrosis progression[J]. Rheumatology (Oxford), 2013, 52(4):679-683. doi: 10.1093/rheumatology/kes358 pmid: 23258649